PLCG2 and/or Btk mutations have been reported to be present in approximately 11% to 90% of ibrutinib-refractory CLL cases, and detection of PLCG2 mutations could be valuable in predicting early relapse in ibrutinib-treated CLL patients 24. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.